Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of leukemia (ALL) that has a protein called CD22 on the cancer cells.
- You have already received a stem cell transplant (from a donor or your own cells) for your leukemia.
- It has been at least 60 days since your transplant.
- You had a high-risk form of leukemia, or your leukemia came back after treatment, or you had minimal disease left before your transplant.
- After transplant, more than 99% of your blood cells come from the donor (if you had a donor transplant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
This trial tests a drug called InO, sometimes given with donor immune cells, for people whose B-cell acute lymphoblastic leukemia or lymphoma came back after a prior stem cell transplant. The goal is to see if it works and is safe.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
Hear when a new Acute Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.